Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.51+0.22 (+1.66%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
Trevi Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Trevi Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$52.63M. For fiscal 2025 it was -$42.09M. The highest annual figure on record is -$18.29M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$42.09M | – |
| FY2024 | Dec 31, 2024 | -$38.26M | – |
| FY2023 | Dec 31, 2023 | -$31.71M | – |
| FY2022 | Dec 31, 2022 | -$28.18M | – |
| FY2021 | Dec 31, 2021 | -$28.95M | – |
| FY2020 | Dec 31, 2020 | -$29.00M | – |
| FY2019 | Dec 31, 2019 | -$23.09M | – |
| FY2018 | Dec 31, 2018 | -$18.29M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.69M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.56M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.68M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.88M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.23M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.90M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.92M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.44M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.73M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.06M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.10M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.73M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.99M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.61M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.95M | – |
See a number that looks wrong?